Literature DB >> 9836323

Clinical manifestations in the West Nile virus outbreak.

E Ceauşu1, S Erşcoiu, P Calistru, D Ispas, O Dorobăţ, M Homoş, C Bărbulescu, I Cojocaru, C V Simion, C Cristea, C Oprea, C Dumitrescu, D Duiculescu, I Marcu, C Mociorniţă, T Stoicev, I Zolotuşca, C Calomfirescu, R Rusu, R Hodrea, S Geamai, L Păun.   

Abstract

During the summer of 1996 an unusual clustering of meningoencephalitis cases was recorded in the Capital City, Bucharest, and in some areas from South-East Romania. After an initial suspicion of an enteroviral etiology was discarded, the West Nile etiology was confirmed by specific antibodies demonstration through hemagglutination-inhibition and ELISA tests. This study included 251 patients with the diagnoses of West Nile acute encephalitis (166 cases), acute meningitis (57 cases) and acute febrile disease (33 cases). The patients' age ranged from 1 to 89 years (mean 51.1 years). The most frequent clinical manifestations were: fever (95.7% of cases), cephalalgia (92.6%), stiffness of the neck (89.1%), vomiting (62.5%), marked asthenia (46.5%), myalgia (28.9%). In addition, patients with encephalitis exhibited: alteration of consciousness (89.2% of cases), tremor of extremities (40.4%), ataxia (44%), paralysis (15.1%). The fatality rate was 15.1% in acute encephalitis, 1.8% in acute meningitis and 0% in the acute febrile disease.

Entities:  

Mesh:

Year:  1997        PMID: 9836323

Source DB:  PubMed          Journal:  Rom J Virol


  19 in total

Review 1.  Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion.

Authors:  Melanie A Samuel; Michael S Diamond
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons.

Authors:  Melanie A Samuel; Kevin Whitby; Brian C Keller; Anantha Marri; Winfried Barchet; Bryan R G Williams; Robert H Silverman; Michael Gale; Michael S Diamond
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  Caspase 3-dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis.

Authors:  Melanie A Samuel; John D Morrey; Michael S Diamond
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

4.  Neurologic sequelae of west nile virus infection.

Authors:  J A Van Gerpen
Journal:  Ochsner J       Date:  2003

5.  West Nile virus infection and its neurological manifestations.

Authors:  Ken Madden
Journal:  Clin Med Res       Date:  2003-04

6.  Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival.

Authors:  Melanie A Samuel; Michael S Diamond
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

7.  The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection.

Authors:  Theodore C Pierson; Qing Xu; Steevenson Nelson; Theodore Oliphant; Grant E Nybakken; Daved H Fremont; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-04-19       Impact factor: 21.023

8.  Estimating biologically relevant parameters under uncertainty for experimental within-host murine West Nile virus infection.

Authors:  Soumya Banerjee; Jeremie Guedj; Ruy M Ribeiro; Melanie Moses; Alan S Perelson
Journal:  J R Soc Interface       Date:  2016-04-13       Impact factor: 4.118

Review 9.  West Nile virus: immunity and pathogenesis.

Authors:  Stephanie M Lim; Penelope Koraka; Albert D M E Osterhaus; Byron E E Martina
Journal:  Viruses       Date:  2011-06-15       Impact factor: 5.048

10.  Clinical characteristics and functional outcome of patients with West Nile neuroinvasive disease in Serbia.

Authors:  Natasa Popovic; Branko Milosevic; Aleksandar Urosevic; Jasmina Poluga; Nada Popovic; Goran Stevanovic; Ivana Milosevic; Milos Korac; Nikola Mitrovic; Lidija Lavadinovic; Jelena Nikolic; Olga Dulovic
Journal:  J Neurol       Date:  2014-04-01       Impact factor: 6.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.